Increased Life Expectancy in Stage IV ALK+ Lung Cancer

Historically, patients with stage IV anaplastic lymphoma kinase-positive (ALK+) lung cancer had a dismal prognosis; between the years 1995 and 2001, only 15% of those with this disease lived past 5 years of diagnosis. However, recent studies show that patients with this cancer have been living longer. In a study published in the Journal of Thoracic Oncology, investigators working for the University of Colorado Cancer Center determined that patients diagnosed with stage IV ALK+ non-small cell lun...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.